FY2025 Earnings Forecast for TMO Issued By Leerink Partnrs

Key Points

• Leerink Partners has raised its FY2025 earnings estimate for Thermo Fisher Scientific to $22.53 per share, up from a previous forecast of $22.32, while the consensus estimate stands at $23.28.
• Thermo Fisher's stock has a market capitalization of $180.67 billion and is currently trading at around $478.61 per share, reflecting a P/E ratio of 27.68.
• The company recently declared a quarterly dividend of $0.43 per share, providing an annualized yield of 0.36%, indicating a healthy dividend payout ratio of 9.95%.

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a research report issued to clients and investors on Wednesday, July 23rd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $22.53 per share for the year, up from their previous forecast of $22.32. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q1 2026 earnings at $5.72 EPS, Q2 2026 earnings at $6.00 EPS and FY2026 earnings at $24.67 EPS.

Several other analysts have also weighed in on TMO. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Barclays raised their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Finally, Evercore ISI dropped their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Six equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $4.25 during mid-day trading on Monday, reaching $481.53. The company had a trading volume of 722,703 shares, compared to its average volume of 2,510,623. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $627.88. The firm has a market cap of $181.77 billion, a price-to-earnings ratio of 27.89, a PEG ratio of 2.58 and a beta of 0.77. The business's 50-day simple moving average is $418.15 and its 200 day simple moving average is $468.92.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific in the 4th quarter worth about $25,000. CBIZ Investment Advisory Services LLC increased its stake in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Finally, Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $31,000. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.